Loading...

Timmerman John

TitleAssociate Professor
InstitutionUniversity of California Los Angeles
DepartmentMedicine
Address42-121 CHS
Campus - 167817
Phone(310) 633-8400 (clinic)
vCardDownload vCard
    Other Positions
    TitleAssociate Professor


    Collapse Research 
    Collapse Research Activities and Funding
    Antibody-CpG conjugates for the treatment of B cell lymphoma
    NIH/NCI R01CA149254Apr 1, 2010 - Feb 28, 2015
    Role: Principal Investigator
    Anti-CTLA-4 Monoclonal Antibody Therapy for Lymphoma
    NIH/NCI R21CA108182Sep 18, 2004 - Aug 31, 2007
    Role: Principal Investigator
    Academic Training in Hematology
    NIH/NHLBI T32HL066992Jul 1, 2001 - Jul 31, 2018
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Timmerman J. The run-down immunologic neighborhood in Hodgkin lymphoma. Blood. 2018 Aug 23; 132(8):770-771. PMID: 30139828.
      View in: PubMed
    2. Young PA, Yamada RE, Trinh KR, Vasuthasawat A, De Oliveira S, Yamada DH, Morrison SL, Timmerman JM. Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha. J Interferon Cytokine Res. 2018 Jun; 38(6):239-254. PMID: 29920129.
      View in: PubMed
    3. Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018 May 10; 36(14):1428-1439. PMID: 29584546.
      View in: PubMed
    4. Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman J, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Ansell S, Kato K, Farsaci B, Sumbul A, Armand P, Neuberg DS, Pinkus GS, Ligon AH, Rodig SJ, Shipp MA. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol. 2018 Apr 01; 36(10):942-950. PMID: 29394125.
      View in: PubMed
    5. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J, Go WY. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017 12 28; 377(26):2531-2544. PMID: 29226797.
      View in: PubMed
    6. Zettlitz KA, Tavaré R, Knowles SM, Steward KK, Timmerman JM, Wu AM. ImmunoPET of Malignant and Normal B Cells with 89Zr- and 124I-Labeled Obinutuzumab Antibody Fragments Reveals Differential CD20 Internalization In Vivo. Clin Cancer Res. 2017 Dec 01; 23(23):7242-7252. PMID: 28928164.
      View in: PubMed
    7. Bhatt S, Parvin S, Zhang Y, Cho HM, Kunkalla K, Vega F, Timmerman JM, Shin SU, Rosenblatt JD, Lossos IS. Anti-CD20-interleukin-21 fusokine targets malignant B cells via direct apoptosis and NK-cell-dependent cytotoxicity. Blood. 2017 04 20; 129(16):2246-2256. PMID: 28137826.
      View in: PubMed
    8. Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90. PMID: 28018601.
      View in: PubMed
    9. Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016 Sep; 17(9):1283-94. PMID: 27451390.
      View in: PubMed
    10. Vasuthasawat A, Yoo EM, Trinh KR, Lichtenstein A, Timmerman JM, Morrison SL. Targeted immunotherapy using anti-CD138-interferon a fusion proteins and bortezomib results in synergistic protection against multiple myeloma. MAbs. 2016 10; 8(7):1386-1397. PMID: 27362935.
      View in: PubMed
    11. Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman J. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol. 2016 Aug 10; 34(23):2698-704. PMID: 27269947; PMCID: PMC5019749 [Available on 08/10/17].
    12. Timmerman J. Hematologic Cancers Break Down a 'Checkpoint': Targeting the PD-1/PD-L1 Axis. Oncology (Williston Park). 2015 Jun; 29(6):440-1. PMID: 26091678.
      View in: PubMed
    13. Yamada DH, Elsaesser H, Lux A, Timmerman JM, Morrison SL, de la Torre JC, Nimmerjahn F, Brooks DG. Suppression of Fc?-receptor-mediated antibody effector function during persistent viral infection. Immunity. 2015 Feb 17; 42(2):379-390. PMID: 25680277; PMCID: PMC4334737.
    14. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015 Jan 22; 372(4):311-9. PMID: 25482239; PMCID: PMC4348009.
    15. Young PA, Morrison SL, Timmerman JM. Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety. Semin Oncol. 2014 Oct; 41(5):623-36. PMID: 25440607; PMCID: PMC4354941.
    16. de Vos S, Forero-Torres A, Ansell SM, Kahl B, Cheson BD, Bartlett NL, Furman RR, Winter JN, Kaplan H, Timmerman J, Whiting NC, Drachman JG, Advani R. A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors. J Hematol Oncol. 2014 Jun 12; 7:44. PMID: 24919462; PMCID: PMC4065310.
    17. Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, Nichols C, Emmanouilides CE, Timmerman JM, Gregory SA, Link BK, Inwards DJ, Freedman AS, Matous JV, Robertson MJ, Kunkel LA, Ingolia DE, Gentles AJ, Liu CL, Tibshirani R, Alizadeh AA, Denney DW. Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. J Clin Oncol. 2014 Jun 10; 32(17):1797-803. PMID: 24799467.
      View in: PubMed
    18. Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D, Or R, Waller EK, Rotem-Yehudar R, Gordon LI. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol. 2013 Nov 20; 31(33):4199-206. PMID: 24127452; PMCID: PMC4878008.
    19. Trinh KR, Vasuthasawat A, Steward KK, Yamada RE, Timmerman JM, Morrison SL. Anti-CD20-interferon-ß fusion protein therapy of murine B-cell lymphomas. J Immunother. 2013 Jun; 36(5):305-18. PMID: 23719241; PMCID: PMC3740795.
    20. Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE, Timmerman J, Said J, Green MR, Delabie J, Kolstad A, Alizadeh AA, Levy R. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood. 2013 Feb 21; 121(8):1367-76. PMID: 23297127; PMCID: PMC3578953.
    21. Betting DJ, Hurvitz SA, Steward KK, Yamada RE, Kafi K, van Rooijen N, Timmerman JM. Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma. J Immunother. 2012 Sep; 35(7):534-43. PMID: 22892450.
      View in: PubMed
    22. Timmerman JM, Byrd JC, Andorsky DJ, Yamada RE, Kramer J, Muthusamy N, Hunder N, Pagel JM. A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. Clin Cancer Res. 2012 Oct 15; 18(20):5752-60. PMID: 22893631.
      View in: PubMed
    23. Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S, Zhao Y, Buyse M, Mackey J, Driga A, Damaraju S, Sliwkowski MX, Robert NJ, Valero V, Crown J, Falkson C, Brufsky A, Pienkowski T, Eiermann W, Martin M, Bee V, Marathe O, Slamon DJ, Timmerman JM. Analysis of Fc? receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res. 2012 Jun 15; 18(12):3478-86. PMID: 22504044; PMCID: PMC3821872.
    24. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011 Jul 01; 17(13):4232-44. PMID: 21540239.
      View in: PubMed
    25. Ai WZ, Kohrt HE, Timmerman J, Hwang J, Hsu FJ, Czerwinski DD, Taidi B, Levy R. Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma. Am J Hematol. 2011 Jun; 86(6):515-8. PMID: 21538469.
      View in: PubMed
    26. Xuan C, Steward KK, Timmerman JM, Morrison SL. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood. 2010 Apr 08; 115(14):2864-71. PMID: 20139095; PMCID: PMC2854431.
    27. Olafsen T, Sirk SJ, Betting DJ, Kenanova VE, Bauer KB, Ladno W, Raubitschek AA, Timmerman JM, Wu AM. ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). Protein Eng Des Sel. 2010 Apr; 23(4):243-9. PMID: 20053640; PMCID: PMC2841542.
    28. Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, Habermann TM, Inwards DJ, Verma M, Yamada R, Erlichman C, Lowy I, Timmerman JM. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2009 Oct 15; 15(20):6446-53. PMID: 19808874; PMCID: PMC2763019.
    29. Varghese B, Widman A, Do J, Taidi B, Czerwinski DK, Timmerman J, Levy S, Levy R. Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees. Blood. 2009 Nov 12; 114(20):4477-85. PMID: 19762487; PMCID: PMC2777127.
    30. Olafsen T, Betting D, Kenanova VE, Salazar FB, Clarke P, Said J, Raubitschek AA, Timmerman JM, Wu AM. Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med. 2009 Sep; 50(9):1500-8. PMID: 19690034; PMCID: PMC2852538.
    31. Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma. J Immunother. 2009 Jul-Aug; 32(6):622-31. PMID: 19483647.
      View in: PubMed
    32. Timmerman JM. Carrier protein conjugate vaccines: the "missing link" to improved antibody and CTL responses? Hum Vaccin. 2009 Mar; 5(3):181-3. PMID: 19246995.
      View in: PubMed
    33. Timmerman JM, Vose JM, Czerwinski DK, Weng WK, Ingolia D, Mayo M, Denney DW, Levy R. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma. 2009 Jan; 50(1):37-46. PMID: 19125383; PMCID: PMC2914563.
    34. Kafi K, Betting DJ, Yamada RE, Bacica M, Steward KK, Timmerman JM. Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines. Mol Immunol. 2009 Jan; 46(3):448-56. PMID: 19046770; PMCID: PMC2768258.
    35. Betting DJ, Mu XY, Kafi K, McDonnel D, Rosas F, Gold DP, Timmerman JM. Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cells. Vaccine. 2009 Jan 07; 27(2):250-9. PMID: 19000731; PMCID: PMC2683685.
    36. Betting DJ, Kafi K, Abdollahi-Fard A, Hurvitz SA, Timmerman JM. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas. J Immunol. 2008 Sep 15; 181(6):4131-40. PMID: 18768870.
      View in: PubMed
    37. Andorsky DJ, Timmerman JM. Interleukin-21: biology and application to cancer therapy. Expert Opin Biol Ther. 2008 Sep; 8(9):1295-307. PMID: 18694350.
      View in: PubMed
    38. Franki SN, Steward KK, Betting DJ, Kafi K, Yamada RE, Timmerman JM. Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo. Blood. 2008 Feb 01; 111(3):1504-11. PMID: 17993615; PMCID: PMC2214758.
    39. Montross S, Timmerman JM. Vaccine therapies for non-Hodgkin's lymphomas. Cancer Treat Res. 2006; 131:283-315. PMID: 16704173.
      View in: PubMed
    40. Hurvitz SA, Timmerman JM. Current status of therapeutic vaccines for non-Hodgkin's lymphoma. Curr Opin Oncol. 2005 Sep; 17(5):432-40. PMID: 16093791.
      View in: PubMed
    41. Hurvitz SA, Timmerman JM. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId. Expert Opin Biol Ther. 2005 Jun; 5(6):841-52. PMID: 15952914.
      View in: PubMed
    42. Timmerman JM, Levy R. Cancer vaccines: pessimism in check. Nat Med. 2004 Dec; 10(12):1279; author reply 1279-80. PMID: 15682512.
      View in: PubMed
    43. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol. 2004 Dec 01; 22(23):4717-24. PMID: 15483014.
      View in: PubMed
    44. Timmerman JM. Therapeutic idiotype vaccines for non-Hodgkin's lymphoma. Adv Pharmacol. 2004; 51:271-93. PMID: 15464914.
      View in: PubMed
    45. Ferl GZ, Timmerman JM, Witte ON. Extending the utility of gene profiling data by bridging microarray platforms. Proc Natl Acad Sci U S A. 2003 Sep 16; 100(19):10585-7. PMID: 12963810; PMCID: PMC196845.
    46. Timmerman JM. Immunotherapy for lymphomas. Int J Hematol. 2003 Jun; 77(5):444-55. PMID: 12841382.
      View in: PubMed
    47. Briones J, Timmerman JM, Panicalli DL, Levy R. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. J Natl Cancer Inst. 2003 Apr 02; 95(7):548-55. PMID: 12671023.
      View in: PubMed
    48. Ribas A, Timmerman JM, Butterfield LH, Economou JS. Determinant spreading and tumor responses after peptide-based cancer immunotherapy. Trends Immunol. 2003 Feb; 24(2):58-61. PMID: 12547500.
      View in: PubMed
    49. Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 2002 Oct 15; 62(20):5845-52. PMID: 12384547.
      View in: PubMed
    50. Timmerman JM. Vaccine therapies for non-Hodgkin's lymphoma. Curr Treat Options Oncol. 2002 Aug; 3(4):307-15. PMID: 12074767.
      View in: PubMed
    51. Briones J, Timmerman J, Levy R. In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. Cancer Res. 2002 Jun 01; 62(11):3195-9. PMID: 12036933.
      View in: PubMed
    52. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002 Mar 01; 99(5):1517-26. PMID: 11861263.
      View in: PubMed
    53. Briones J, Timmerman JM, Hilbert DM, Levy R. BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol. 2002 Feb; 30(2):135-41. PMID: 11823048.
      View in: PubMed